Related Experiment Video
Updated: Jun 27, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
[Association between lysosomal cysteine protease cathepsin's activation and left ventricular function and remodeling
Xian-Wu Cheng1, Jie Zhang, Hui Song
1Department of Cardiovascular Research Medicine, Nagoya University School of Medicine, Aichiken, Nagoya 466-8550, Japan. xianwu@med.nagoya-u.ac.jp
Insights
Cathepsin S (Cat S) expression and activity increase in hypertensive heart failure, contributing to myocardial remodeling. Targeting Cat S may offer a new therapeutic strategy for heart failure.
Area of Science:
- Cardiovascular Biology
- Enzymology
- Pathophysiology
Context:
- Hypertension leads to cardiac remodeling and heart failure.
- The role of specific proteases in this process is not fully understood.
- Cathepsin S (Cat S) is a cysteine protease implicated in various biological functions.
Purpose:
- To investigate the expression and activity of Cat S in the myocardium of rats with hypertension-induced heart failure.
- To examine the correlation between Cat S and cardiac function.
- To explore the potential role of Cat S in myocardial remodeling.
Summary:
- Cat S mRNA and activity were significantly upregulated in the left ventricular myocardium of rats with heart failure compared to hypertrophy or control groups.
- Cat S expression negatively correlated with left ventricular ejection fraction (LVEF).
- Increased Cat S activity was associated with elastic lamina fragmentation and elevated interleukin-1 beta levels, suggesting a role in myocardial remodeling.
Impact:
- Cathepsin S (Cat S) is implicated in the pathogenesis of myocardial remodeling and heart failure.
- Cat S may represent a novel therapeutic target for preventing or reversing hypertension-induced left ventricular remodeling and heart failure.
- Findings were corroborated in human myocardial specimens.
Objective:
To observe myocardial cathepsin (Cat) S expression and activity in hypertensive heart failure rats.
Methods:
The expression and activity of Cat S were determined in the left ventricular (LV) myocardium (LVM) of Dahl salt-sensitive rats fed either a high-salt (HS, 8%) or low-salt (LS, 0, 3%, controls) diet starting at age 7 weeks for 12 weeks (hypertrophy model, H-LVH) or 19 weeks (heart failure model, H-HF). Age-matched rats served as controls and human normal, hypertensive and heart failure myocardial specimen were also examined for changes on the expression and activity of Cat S.
Results:
Reverse transcription and real-time polymerase chain reaction analysis revealed significantly upregulated Cat S mRNA in rats with H-HF than in rats with H-LVH or in control rats and Cat S mRNA expression is negatively correlated with LVEF (r = -0.88, P < 0.05). In situ and immunohistochemistry examinations showed that Cat S was localized predominantly in cardiac myocytes (CMCs) and coronary vascular smooth muscle cells (SMC). Elastic lamina fragmentations and Cat S-dependent elastolytic activity were significantly increased in H-HF-rats. The expression of interleukin-1 beta was also increased in the LVM of H-HF rats, and this cytokine was found to increase the Cat S protein expression in culture neonatal CMCs. Similar results were revealed in human myocardial specimens.
Conclusion:
Elastolytic Cat S might play an important role in the pathogenesis of myocardial remodeling and heart failure and Cat S might serve as a novel therapeutic target in preventing or reversing hypertension induced LV remodeling and heart failure.
More Related Videos
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System